Please Wait
Applying Filters...
menu
    • menu
    DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Sept 2024: BMS wins landmark FDA approval for schizophrenia med; Sanofi’s Dupixent okayed for COPD

    Stock Recap
    #PipelineProspector

    Menu

    Ceftriaxone

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 110Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Registrant Name MF Registration No. Classification Initial Date of Reg. Latest Date of Reg. Registrant's Address
    26/09/2024 Hanmi Pharmaceutical
    South Korea
    		 HANMI FINE CHEMICAL CO. , LTD. 219MF10097 Ceftriaxone sodium hydrate 2007-03-14 2018-01-19 57, Gyeongje-ro, Siheung-si, Gyeonggi-do, Korea
    26/09/2024 Kyongbo Pharmaceutical Co., Ltd
    South Korea
    		 Kyongbo Pharmaceutical Co. , Ltd. 302MF10121 Ceftriaxone sodium hydrate 2020-10-05 2020-10-05 174, Sirok-ro, Asan-si, Chungcheongnam-do, KOREA